Subscribe

Study Summaries

XIA-2025: Camrelizumab + Famitinib vs Camrelizumab vs Chemotherapy in Recurrent/Metastatic Cervical Cancer (Randomized Phase II)

Camrelizumab plus famitinib significantly improves response rate and survival outcomes compared to camrelizumab alone or chemotherapy in pretreated R/M CC with a manageable safety profile.

ROSELLA (GOG-3073/ENGOT-ov72): Relacorilant plus Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer

Relacorilant plus nab-paclitaxel significantly prolonged PFS and showed a clinically meaningful interim OS improvement versus nab-paclitaxel alone, with manageable toxicity, positioning the combination as a potential new standard for platinum-resistant ovarian cancer.

SOLO-3: Olaparib vs. Chemotherapy in PSROC

Olaparib significantly improved PFS and ORR over nonplatinum chemotherapy, though no OS benefit was observed in the overall population. In patients with ≥3 prior therapies, chemotherapy had more favorable OS.

NRG-GY023: Durvalumab, Olaparib, and Cediranib vs Chemotherapy in Platinum-Resistant Ovarian Cancer with Prior Bevacizumab

The addition of durvalumab with olaparib and cediranib did not improve PFS in platinum-resistant ovarian cancer patients with prior bevacizumab exposure.

ARIEL 4

PALETTE: Pazopanib for Metastatic Soft-Tissue Sarcoma

PALEO Trial: Palbociclib + Letrozole in Endometrial Cancer

The combination of palbociclib and letrozole significantly improved PFS compared to placebo with letrozole. However, it was associated with higher hematologic toxicities, particularly neutropenia.

Fulvestrant + Abemaciclib

The combination of abemaciclib and fulvestrant shows promising efficacy and manageable toxicity in HR-positive advanced or recurrent endometrial cancer, especially in CN-L/NSMP tumors

LEAP-001: Lenvatinib plus Pembrolizumab vs. Chemotherapy as First-Line Therapy for Advanced Endometrial Cancer

First-line lenvatinib plus pembrolizumab did not significantly improve PFS or OS compared to chemotherapy in mismatch repair-proficient (pMMR) advanced endometrial cancer. Toxicity was higher in the experimental arm but manageable. dMMR exploratory analysis shows promise in this subgroup.

CHIPOR: Secondary Debulking and HIPEC in Platinum-Sensitive Recurrent Ovarian Cancer

HIPEC combined with cytoreductive surgery significantly improved overall survival and progression-free survival in recurrent ovarian cancer